Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental HIV vaccine shows promise in early safety trial

NCT ID NCT05781542

First seen Nov 14, 2025 · Last updated May 21, 2026 · Updated 28 times

Summary

This early-stage study tested a new type of HIV vaccine in 46 healthy adults without HIV. The vaccine uses synthetic DNA to train the immune system, with some participants also receiving a protein boost. The main goal was to check safety and see if the vaccine triggers a strong immune response against HIV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alabama CRS (Site ID: 31788)

    Birmingham, Alabama, 35294, United States

  • Bridge HIV CRS

    San Francisco, California, 94102, United States

  • Brigham and Women's Hospital Vaccine CRS [30007]

    Boston, Massachusetts, 02115, United States

  • CAPRISA eThekwini CRS

    Durban, KwaZulu-Natal, 4013, South Africa

  • Durban Adult HIV CRS

    Durban, KwaZulu-Natal, South Africa

  • Groote Schuur HIV CRS (Site ID: 31708)

    Cape Town, Western Cape, 7925, South Africa

  • San Francisco Vaccine and Prevention CRS

    San Francisco, California, 94102, United States

  • Soweto HVTN CRS

    Johannesburg, Gauteng, South Africa

Conditions

Explore the condition pages connected to this study.